Cocrystal Pharma, Inc. (COCP) vs TScan Therapeutics, Inc. (TCRX)

Cocrystal Pharma, Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. Cocrystal Pharma, Inc. and TScan Therapeutics, Inc. are of similar size ($23.7M and $22.2M). TScan Therapeutics, Inc. grew revenue faster over the last twelve months: 2.15% against −30.4%. Cocrystal Pharma, Inc. has the higher net margin (−747.8% vs −1,655.4%) and the higher return on invested capital (0.00% vs −4,588.2%). Across the 18 metrics below, Cocrystal Pharma, Inc. leads on 9 and TScan Therapeutics, Inc. on 9.

Valuation

Metric COCP TCRX Biotechnology median
P/E n/m n/m 7.88
P/S 12.14 6.21 11.47
P/B 15.45 0.64 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.20 0.74
EV/Sales 10.46 (3.26) 10.73
Earnings yield (64.96%) (267.65%) (28.84%)
Free cash flow yield (49.38%) (268.00%) (23.03%)

Profitability

Metric COCP TCRX Biotechnology median
Gross margin 9.10% 100.00% 65.16%
Operating margin (760.72%) (1,695.15%) 0.00%
Net margin (747.78%) (1,655.35%) 0.00%
Free cash flow margin (598.50%) (1,665.18%) 0.00%
Return on equity (311.68%) (95.80%) (57.72%)
Return on assets (151.10%) (50.09%) (49.22%)
Return on invested capital 0.00% (4,588.23%) 0.00%

Growth

Metric COCP TCRX Biotechnology median
Revenue growth (TTM) (30.38%) 2.15% 5.64%
EPS growth (last fiscal year) 54.65% 12.28% —
Revenue growth, 5-year CAGR (33.30%) 56.92% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric COCP TCRX Biotechnology median
Debt to equity 0.00 0.47 0.00
Current ratio 1.24 3.37 4.73
Net debt to EBITDA 0.82 0.90 0.96

Dividend

Metric COCP TCRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric COCP TCRX Biotechnology median
Market cap 22.15m 23.65m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack